Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$12.26 USD
-0.50 (-3.92%)
Updated Sep 26, 2024 04:00 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Stoke Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 201 | 230 | 220 | 287 | 222 |
Receivables | 0 | 1 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 14 | 14 | 9 | 7 | 3 |
Total Current Assets | 215 | 244 | 229 | 294 | 226 |
Net Property & Equipment | 6 | 7 | 4 | 3 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 0 | 0 |
Total Assets | 228 | 256 | 239 | 298 | 229 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 2 | 2 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 14 | 16 | 15 | 10 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 15 | 15 | 0 | 0 | 0 |
Total Current Liabilities | 31 | 31 | 17 | 11 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 33 | 37 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 3 | 4 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 69 | 71 | 21 | 12 | 4 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 561 | 483 | 414 | 396 | 282 |
Retained Earnings | -402 | -297 | -196 | -110 | -58 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 160 | 185 | 218 | 286 | 224 |
Total Liabilities & Shareholder's Equity | 228 | 256 | 239 | 298 | 229 |
Total Common Equity | 160 | 185 | 218 | 286 | 224 |
Shares Outstanding | 44.60 | 39.40 | 36.70 | 33.40 | 32.70 |
Book Value Per Share | 3.58 | 4.69 | 5.93 | 8.57 | 6.86 |
Fiscal Year End for Stoke Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 282 | 179 | 201 | 215 | 231 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 15 | 15 | 14 | 15 | 15 |
Total Current Assets | 297 | 193 | 215 | 230 | 246 |
Net Property & Equipment | 5 | 5 | 6 | 6 | 6 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 1 | 1 | 1 | 1 |
Total Assets | 308 | 205 | 228 | 240 | 257 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 2 | 2 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 15 | 13 | 14 | 13 | 12 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 26 | 21 | 15 | 9 | 8 |
Total Current Liabilities | 45 | 36 | 31 | 25 | 22 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 17 | 25 | 33 | 41 | 43 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 5 | 1 | 2 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 65 | 65 | 69 | 67 | 67 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 697 | 569 | 561 | 548 | 541 |
Retained Earnings | -454 | -428 | -402 | -375 | -350 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 243 | 140 | 160 | 173 | 190 |
Total Liabilities & Shareholder's Equity | 308 | 205 | 228 | 240 | 257 |
Total Common Equity | 243 | 140 | 160 | 173 | 190 |
Shares Outstanding | 52.10 | 52.10 | 44.60 | 44.60 | 44.10 |
Book Value Per Share | 4.66 | 2.69 | 3.58 | 3.88 | 4.31 |